source
- BioNTech trims full-year COVID-19 vaccine sales outlook by up to 20% amid weak demandBioNTech announced it is lowering its full-year sales guidance for its COVID-19 vaccine. The company cut the midpoint of its outlook by almost 20%, moving the range to €1.6-1.9 billion from the pr…
- Pfizer adds $2.5 billion to restructuring, targeting $6 billion savings by 2029Pfizer announced an additional $2.5 billion in cost reductions as part of its ongoing restructuring program. The new cuts focus on technology and simplification across commercial, R&D and manufact…